Effect of neoadjuvant buparlisib on PI3K/AKT/mTOR signaling pathway in PI3KCA mutated early breast cancer

Trial Profile

Effect of neoadjuvant buparlisib on PI3K/AKT/mTOR signaling pathway in PI3KCA mutated early breast cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2014

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 19 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top